Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia
Urinary Ascorbyl Peroxide as an Early Biological Marker of Bronchopulmonary Dysplasia in Preterm Infants Less Than 33 Weeks of Gestation
2 other identifiers
observational
51
1 country
1
Brief Summary
Urinary ascorbyl peroxide level in the first week of life will be a good predictor of Bronchopulmonary dysplasia (BPD) in preterm infants less than 33 weeks of gestation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Aug 2010
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2010
CompletedFirst Submitted
Initial submission to the registry
September 16, 2011
CompletedFirst Posted
Study publicly available on registry
September 23, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2015
CompletedNovember 18, 2015
November 1, 2015
5.3 years
September 16, 2011
November 17, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Bronchopulmonary Dysplasia
To correlate the level of urinary Ascorbyl peroxide and BPD. Full diagnosis and classification (to mild, moderate or severe) is at 36 weeks of corrected age; so even for most premature infants (like 23 weeks of gestation) there will be a need for follow up for less than 4 month to have the final diagnosis at 36 weeks
4 Months
Secondary Outcomes (2)
The redox status (in blood)
First week of life (week 1) and 36 semaines CA
Major neonatal outcomes (NEC, ROP, PDA, IVH, PVL)
4 Months
Study Arms (1)
Preterm less than 33 weeks
This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
Eligibility Criteria
Preterm infants less than 33 weeks of getation
You may qualify if:
- Preterm infants less than 33 weeks of gestation\<
- Admission to CHU Sainte-JUstien neonatal intensive care unit
- Receiving Parenteral nutrition during the first week of life
- Parental consent
You may not qualify if:
- Major congenital anomalies
- Sever perinatal asphyxia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Montreal, Sainte-Justine Hospital
Montreal, Quebec, H3T1C5, Canada
Related Links
- Neonatal Exposure to Oxidants Induces Later in Life a Metabolic Response Associated to a Phenotype of Energy Deficiency in an Animal Model of Total Parenteral Nutrition
- Admixture of a Multivitamin Preparation to Parenteral Nutrition: The Major Contributor to In Vitro Generation of Peroxides
- Paradoxical Role of Ascorbic Acid and Riboflavin in Solutions of Total Parenteral Nutrition: Implication in Photoinduced Peroxide Generation
Biospecimen
Urine sample (650 µl) Blood sample (500 µl)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ibrahim Mohamed, Mb CHB
University of Montreal, Sainte Justine Hospital
- STUDY DIRECTOR
Jean-claude Lavoie, PhD
University of Montreal, Sainte-Justine hospital research center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Adjunct professor of peditarics, division of neonatology
Study Record Dates
First Submitted
September 16, 2011
First Posted
September 23, 2011
Study Start
August 1, 2010
Primary Completion
November 1, 2015
Study Completion
November 1, 2015
Last Updated
November 18, 2015
Record last verified: 2015-11